Literature DB >> 10759783

Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).

C Ribbens1, V Bonnet, M J Kaiser, B Andre, O Kaye, N Franchimont, D de Groote, Y Beguin, M G Malaise.   

Abstract

Synovial fluid (SF) levels of soluble CD23 (sCD23) were determined in 96 patients presenting with an inflammatory knee effusion (73 with RA and 23 with reactive arthritis (ReA) serving as a control inflammatory non-erosive group) and were correlated with the degree of joint destruction, with local immune parameters (IL-1beta, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12 and sCD25) and with serum markers of inflammation, C-reactive protein and erythrocyte sedimentation rate. RA patients, classified as erosive or not according to Larsen's grade, were separated as follows: (i) 13 patients with non-erosive RA; (ii) 16 RA patients with erosions in hands but not in knees, matched for disease duration with the first group; (iii) 44 RA patients with hand and knee erosions, matched with the second group for rheumatoid factor positivity but of longer disease duration. SF sCD23 levels were significantly increased in both erosive RA groups compared with non-erosive diseases, whether RA or ReA (P < 0.05), whose SF levels were not different. SF IL-10 showed a similar profile to that of SF sCD23 and was the only other parameter characteristic of erosive RA, but no direct correlation was found between the two. SF sCD23 was significantly correlated with IL-12 (r = 0.65, P = 0.0001) and sCD25 (r = 0.39, P = 0.0019) exclusively in the two erosive RA populations. In conclusion, these data showing that increased levels of sCD23 are not only found in the SF of erosive joints but also in knee SF of patients with erosive RA but without knee x-ray-diagnosed erosions suggest that this parameter might be of predictive value for joint destruction. Longitudinal studies are however needed to confirm its potential clinical interest.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759783      PMCID: PMC1905611          DOI: 10.1046/j.1365-2249.2000.01198.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

Review 1.  The low-affinity receptor for IgE.

Authors:  G Delespesse; M Sarfati; C Y Wu; S Fournier; M Letellier
Journal:  Immunol Rev       Date:  1992-02       Impact factor: 12.988

Review 2.  Biological properties of interleukin 10.

Authors:  M Howard; A O'Garra; H Ishida; R de Waal Malefyt; J de Vries
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

Review 3.  Expression, structure, and function of the CD23 antigen.

Authors:  G Delespesse; U Suter; D Mossalayi; B Bettler; M Sarfati; H Hofstetter; E Kilcherr; P Debre; A Dalloul
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

4.  Detection of circulating Fc epsilon R2/CD23+ monocytes in patients with rheumatic diseases.

Authors:  H Becker; P Potyka; C Weber; K Federlin
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

5.  Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  A Bansal; T Roberts; E M Hay; R Kay; R S Pumphrey; P B Wilson
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

6.  Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4.

Authors:  P Chomarat; J Briolay; J Banchereau; P Miossec
Journal:  Arthritis Rheum       Date:  1993-02

7.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

8.  Serum levels of soluble IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases.

Authors:  T Matsumoto; T Miike; K Yamaguchi; M Murakami; T Kawabe; J Yodoi
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

Review 9.  Expression, regulation and function of human Fc epsilon RII (CD23) antigen.

Authors:  M Sarfati; S Fournier; C Y Wu; G Delespesse
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

10.  Regulation of cytokine production by soluble CD23: costimulation of interferon gamma secretion and triggering of tumor necrosis factor alpha release.

Authors:  M Armant; H Ishihara; M Rubio; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  6 in total

Review 1.  CD23/FcεRII: molecular multi-tasking.

Authors:  M Acharya; G Borland; A L Edkins; L M Maclellan; J Matheson; B W Ozanne; W Cushley
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells.

Authors:  Aleta Pupovac; Nicholas J Geraghty; Debbie Watson; Ronald Sluyter
Journal:  Immunol Cell Biol       Date:  2014-08-26       Impact factor: 5.126

Review 3.  The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity.

Authors:  David R Gibb; Sheinei J Saleem; Natalia S Chaimowitz; Joel Mathews; Daniel H Conrad
Journal:  Mol Immunol       Date:  2011-01-13       Impact factor: 4.407

Review 4.  Soluble IgE receptors--elements of the IgE network.

Authors:  Barbara Platzer; Floortje Ruiter; John van der Mee; Edda Fiebiger
Journal:  Immunol Lett       Date:  2011-09-06       Impact factor: 3.685

5.  ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo.

Authors:  David R Gibb; Mohey El Shikh; Dae-Joong Kang; Warren J Rowe; Rania El Sayed; Joanna Cichy; Hideo Yagita; John G Tew; Peter J Dempsey; Howard C Crawford; Daniel H Conrad
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

6.  Expression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesis.

Authors:  Koichiro Komiya; Hiroyuki Enomoto; Isao Inoki; Satoko Okazaki; Yoshinari Fujita; Eiji Ikeda; Eiko Ohuchi; Hideo Matsumoto; Yoshiaki Toyama; Yasunori Okada
Journal:  Arthritis Res Ther       Date:  2005-08-05       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.